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Gephyrin (GPHN) is an organizational protein that
clusters and localizes the inhibitory glycine (GlyR) and
GABAA receptors to the microtubular matrix of the neu-
ronal postsynaptic membrane. Mice deficient in gephy-
rin develop a hereditary molybdenum cofactor defi-
ciency and a neurological phenotype that mimics startle
disease (hyperekplexia). This neuromotor disorder is as-
sociated with mutations in the GlyR 1 and  subunit
genes (GLRA1 and GLRB). Further genetic heterogene-
ity is suspected, and we hypothesized that patients lack-
ing mutations in GLRA1 and GLRB might have muta-
tions in the gephyrin gene (GPHN). In addition, we
adopted a yeast two-hybrid screen, using the GlyR 
subunit intracellular loop as bait, in an attempt to
identify further GlyR-interacting proteins implicated
in hyperekplexia. Gephyrin cDNAs were isolated, and
subsequent RT-PCR analysis from human tissues dem-
onstrated the presence of five alternatively spliced
GPHN exons concentrated in the central linker region of
the gene. This region generated 11 distinct GPHN tran-
script isoforms, with 10 being specific to neuronal tis-
sue. Mutation analysis of GPHN exons in hyperekplexia
patients revealed a missense mutation (A28T) in one
patient causing an amino acid substitution (N10Y).
Functional testing demonstrated that GPHNN10Y does
not disrupt GlyR-gephyrin interactions or collybistin-
induced cell-surface clustering. We provide evidence
that GlyR-gephyrin binding is dependent on the pres-
ence of an intact C-terminal MoeA homology domain.
Therefore, the N10Y mutation and alternative splicing
of GPHN transcripts do not affect interactions with
GlyRs but may affect other interactions with the cy-
toskeleton or gephyrin accessory proteins.
Neuronal postsynaptic membranes contain a wide variety of
ion channels and receptor proteins that contribute to the bal-
ance of excitatory and inhibitory neurotransmission in the
human central nervous system. Mature postnatal neuroinhibi-
tion is mediated by postsynaptic glycinergic and GABAA
1 re-
ceptor systems that are structurally related to the nicotinic
receptors with a typical pentameric structure constructed from
heterogeneous subunit constituents containing four transmem-
brane (TM) domains and a large intracellular loop between
TM3 and TM4 (1, 2). These subunits combine to form fast
response, ligand-gated chloride channels that modify excita-
tory neurotransmission in the human brainstem and spinal
cord (3–5). Inhibitory glycine receptors (GlyRs) are composed of
three ligand-binding 1 subunits (GlyR 1) and two structural
 subunits (GlyR ) that are anchored and clustered on the
postsynaptic membrane of inhibitory neurons by the interac-
tion of a motif within the TM3-TM4 loop of the GlyR subunit
with anchoring protein, gephyrin (6–8). In contrast to GlyRs,
there is a lack of evidence for a direct physical interaction
between gephyrin and GABAA receptor subunit(s) (7, 9), al-
though immunohistochemical studies have detected co-local-
ization of gephyrin with major subtypes of GABAA receptors at
GABAergic postsynaptic sites in murine and rat brain (10–14).
Gephyrin (GPHN) belongs to a group of cytoskeletal ele-
ments that are critical for receptor-associated synaptic local-
ization and organization. First identified as a 93-kDa protein
by co-purification with GlyRs from rat spinal cord, GPHN dem-
onstrated high affinity binding to tubulin (15–17). It is sug-
gested that gephyrin forms a postsynaptic organizational lat-
tice structure that dynamically immobilizes and clusters
inhibitory receptors onto the cytoskeletal infrastructure (14,
18). In support of this, GPHN-dependent postsynaptic cluster-
ing of GlyRs was demonstrated by cellular antisense experi-
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ments and from studies of a gphn knock-out mouse model (12,
19, 20). Heterogeneous roles for gephyrin have been implicated
by protein-protein interactions with a range of determinants
such as RAFT1, tubulin, profilin, collybistin, and the dynein
light chains 1 and 2 (17, 21–24).
The preliminary structure of the gephyrin gene (GPHN) has
been described in mice and humans (25–27), although there is
a degree of ambiguity in the number of exons due to the pres-
ence of multiple transcript isoforms, and it is uncertain that all
exons have been located and identified. Indeed, GPHN expres-
sion is not restricted to rat brain and spinal cord but is also
found in liver, kidney, lung, and retina (28–30). Gephyrin
knock-out mice and reconstitutive cell culture assays have
demonstrated that gephyrin expression in nonneuronal tissue
is a requirement for the biosynthesis of molybdenum cofactor
(20, 31). Striking homologies are observed between the primary
structure of GPHN and proteins involved in bacterial, plant,
and invertebrate molybdenum cofactor biosynthesis. Gephyrin,
therefore, has a synaptic function as a postsynaptic anchoring
and clustering protein in neurons while facilitating a highly
conserved metabolic purpose in nonneuronal tissues (32). The
genetic and structural basis of the functional dichotomy is not
established; however, in rats, a putative explanation may lie in
the generation of distinct transcript isoforms of gephyrin con-
structed from alternative splicing of eight exonic “cassettes”
within four regions of GPHN (25, 28, 33). Apart from conferring
neuronal and nonneuronal characteristics to the mature
polypeptide products, the purpose of the transcript heteroge-
neity pattern is unclear, and the number of isoform combina-
tions in human tissue remains unestablished.
In addition to major disruption of molybdenum cofactor bio-
synthesis, gephyrin-deficient mice display a neuromotor phe-
notype, which resembles human hereditary hyperekplexia.
This neurological condition (Mendelian Inheritance of Man:
149400 and 138491) can be caused by dominant and recessive
mutations in the GLRA1 and GLRB receptor genes and is
characterized by an abnormal, persistent startle response to
unexpected stimuli, neonatal hypertonia, and a chronic accu-
mulation of injuries caused by unprotected, startle-induced
falls (34–40). Furthermore, autoimmunity to GPHN was de-
tected in a patient with Stiff-Man syndrome, a disorder that
has a degree of phenotypic overlap with hyperekplexia (41).
Collectively, this indicates that GPHN is a candidate gene for
neurological and metabolic disorders, and support for the latter
has recently emerged with a description of a GPHN reading
frame mutation in a family with hereditary molybdenum co-
factor deficiency (42).
In response to the candidacy of gephyrin for hyperekplexia,
we pursued the definitive genomic structure of gephyrin by a
combination of in silico BAC contig construction and multitis-
sue RT-PCR methods. Using a yeast two-hybrid (YTH) screen,
with the GlyR  subunit intracellular loop as bait, we at-
tempted to identify further GlyR-interacting proteins that
might be implicated in hyperekplexia. The results of this
screen, together with the extensive search for all human GPHN
transcripts in both neuronal and nonneuronal tissues, suggest
the presence of one new GPHN exon and at least 11 neurolog-
ical transcript isoform combinations that redefine the genomic
organization of GPHN. Having established the number of ex-
ons in the GPHN gene, we completed a systematic exon by exon
mutation analysis of GPHN in a cohort of hyperekplexia pa-
tients devoid of GLRA1 and GLRB mutations. One novel mu-
tation (N10Y) and several SNPs are reported; however, the
functional effect of the mutation remains elusive despite assays
for receptor targeting and clustering. We also present evidence
that GlyR-gephyrin binding is dependent on the presence of an
intact C-terminal MoeA homology domain and that the heter-
ogeneous GPHN linker region is not the physical determinant
for gephyrin-GlyR binding.
MATERIALS AND METHODS
RT-PCR Analysis of GPNH Alternative Splicing—A GPHN gene-
specific primer (Table I) was used in a first-strand cDNA synthesis
reaction (SuperScript II; Invitrogen) from total RNA derived from adult
brain, fetal brain, cerebellum, and human spinal cord (Clontech). In
addition to neurological tissue, cDNA was synthesized from a selection
of nonneurological tissues including heart, liver, lung, kidney, trachea,
fetal liver, pancreas, and placenta (Clontech). In the first instance,
exonic primers were designed in constitutional regions surrounding the
candidate regions of alternative splicing, namely regions C1/2, C3, C4/5,
and C6/7 (Table I). To validate the initial RT-PCR methodology, down-
stream nested primers within the GPHN spliced exons were used in
conjunction with primers from upstream invariant portions of the
GPHN message (Table I). In the presence of multiple PCR products,
DNA fragments were cloned into pGEM-Easy vectors (Stratagene), and
the transformants were PCR-screened and assessed for size differences
by molecular screening agarose (Roche Applied Sciences) and 10% non-
denaturing polyacrylamide gels (Sigma). Minipreparations of clones
were digested with EcoRI, and inserts were sequenced using ABI 3100
technology.
YTH Screening—To identify GlyR  subunit interactors in human
brain, we cloned the large intracellular loop of the human GlyR 
subunit into the plasmid vector pYTH9 (43, 44). In this manner, the
large TM3-TM4 intracellular loop (known to harbor a gephyrin binding
motif) (8) was fused to the GAL4 DNA binding domain. pYTH9 is
advantageous for YTH screening, since the bait plasmid can be stably
integrated into the yeast genome at the trp-1 locus. An adult human
brain cDNA library in pACT2 (HL4004AH; Clontech) was be screened
by transformation of library DNA into the pYTH9-GlyR  yeast strain.
Transformed yeast were plated on selective dropout media lacking
leucine, tryptophan, and histidine, supplemented with 10 mM 3-amino-
1,2,4-triazole, a competitive inhibitor of the HIS3 gene product. Trans-
formation plates were incubated at 30 °C for 12 days to allow histidine
prototropic colonies to emerge. Surviving colonies were restreaked onto
selective agar, lifted onto Whatman 54 paper, and screened for protein-
protein interactions using a standard freeze-thaw fracture assay for the
lacZ reporter gene (44). Library plasmid DNAs were recovered from
-galactosidase-positive colonies using the Yeastmaker plasmid isola-
tion kit (Clontech), transformed into Escherichia coli XL1-blue (Strat-
agene), miniprepped, and sequenced. True interactions were checked by
retransformation of library plasmids into yeast containing pYTH16 (an
episomal version of pYTH9) and pYTH16-GlyR . Library plasmids that
were capable of autoactivation (i.e. activated lacZ with pYTH16 alone)
were excluded from further analysis.
Constructs, Human Embryonic Kidney (HEK) Cell Transfection, and
Confocal Microscopy—For the pDSRed-GlyR  construct, the large in-
tracellular loop of the human GlyR  subunit was amplified using the
primers BDSRed1 (5-GCTGAATTCGCCACCATGGCAGTTGTCCAG-
GTGATGCT-3) and BDSRed2 (5-AACGGATCCCTTGCATAAAGATC-
AATTCGC-3) and cloned into the EcoRI and BamHI sites of
pDSRed-N1 (Clontech). For the pEGFP-gephyrin construct, the entire
coding region of the rat gephyrin P1 isoform (28) was amplified using
the primers G1 (5-CGCTGATCAACATGGCGACCGAGGGA-3) and
G14 (5-TGGCTCGAGTCATAGCCGTCCGATGA-3), cut with BclI and
XhoI, and cloned into the BglII and SalI sites of pEGFPC2 (Clontech).
The N10Y mutation was introduced into pEGFP-gephyrin by site-direc-
ted mutagenesis, using 27-mer oligonucleotides and the QuikChange
kit (Stratagene). Collybistin cDNAs were amplified from postnatal (P0)
rat brain first-strand cDNA using the primers CB1 (5-GTGGGATCC-
ATGCAGTGGATTAGAGGCGGA-3) and CB3 (5-TTAGAATTCTCTG-
CCTTCCTATAGGTATTA-3 and cloned into the BamHI and EcoRI and
sites of the vector pRK5myc. The construct used in this study
(pRK5mycCB2SH3) encodes the collybistin II isoform (23). All
amplifications were performed using Pfu Turbo proofreading DNA
polymerase (Stratagene), and DNAs for transfection were made using
the Plasmid Maxi Kit (Qiagen). All constructs were sequenced using the
BigDye ready reaction mix (PerkinElmer Life Sciences) and an ABI 310
automated DNA sequencer (Applied Biosystems).
HEK cells (ATCC CRL1573) were grown in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal calf serum, 2 mM glutamine,
100 units ml1 penicillin G, and 100 mg ml1 streptomycin at 37 °C in
95% air-5% CO2 (45). Exponentially growing cells were electroporated
(400 V, infinite resistance, 125 microfarads; Bio-Rad Gene Electro-
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pulser II) with various combinations of three plasmid constructs: pD-
SRed-GlyR , pEGFP-gephyrinN10Y, or pRK5myc-collybistin II. After
24 h, cells were washed twice in phosphate-buffered saline and fixed for
5 min in 4% (w/v) phosphonoformic acid (PFA) in phosphate-buffered
saline. Myc-tagged collybistin II was detected using an anti-9E10 mono-
clonal antibody (Sigma) and TRITC-conjugated secondary antibodies
(Jackson ImmunoResearch) using standard protocols. Confocal micros-
copy was performed as previously described (46).
In Silico Determination of Human Gephyrin Gene Structure—Rat
cDNA (28) and human expressed tag sites similar to rat gephyrin were
submitted for BLAST searches (available on the World Wide Web at
www.ncbi.nlm.nih.gov/BLAST/). Portions of rat cDNA fragments dis-
played 90–95% homology with dispersed regions of several chromosome
14 human genome BACs submitted to GenBankTM. Exon/intron orga-
nization was established from the genomic BAC contig, and a putative
promoter region was identified through sequence homologies. Details of
the human GPHN gene have subsequently been described by David-
Watine (27), and the BAC clones are accessible from GenBankTM.
Hyperekplexia Patients—The majority of patients included in the
mutation analysis of the GPHN gene (n  31) are described elsewhere
(37). In addition, a further seven unrelated hyperekplexia patients all
exhibited to the diagnostic criteria of inclusion, which involves a history
of neonatal hypertonia, a nose tap response, and an exaggerated startle
response, leading to injurious fall down consequences with preservation
of consciousness.
PCR Analysis of GPHN in Hyperekplexia—The GPHN promoter re-
gion, exons and flanking intronic sequences, and 5- and 3-untrans-
lated regions were amplified from patient DNA. Primer sets were de-
signed by Primer 3.0 criteria via the online facility (available on the
World Wide Web at www-genome.wi.mit.edu/cgi-bin/primer/primer3.0).
Each 25-l reaction contained 60 ng of genomic DNA, 10 pmol of each
primer, 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 200 M
dNTPs (Amersham Biosciences), and 1 unit of Taq polymerase (Qia-
gen). Promoter regions were amplified with Expand Fidelity Taq (Roche
Applied Science) accompanied by 10% (v/v) Me2SO (Sigma) because of
the high GC content of the region. The DNA was amplified in MJ
Research or PerkinElmer Life Sciences thermocyclers.
SSCP—Samples for screening were prepared by denaturing 5 l of
GPHN PCR products with 7 l of formamide dye at 94 °C for 5 min.
Samples were cooled and applied to 10% nondenaturing gels (49:1;
Sigma) and run at 75 V for 12–16 h at room temperature and 4 °C. All
SSCP gels were silver-stained as previously described (47).
Bidirectional Dideoxy Fingerprinting (DDF) Analysis—DDF analysis
was carried out using [-33P]ddNTP/dNTP mixtures and thermoseque-
nase reactions (Amersham Biosciences). DDF patterns for GPHN as-
says were resolved on MDE nondenaturing gels (48, 49).
dHPLC—Analysis was carried out using the Transgenomics dHPLC
2100 WAVER DNA Fragment Analysis System and DNASepR column
(Transgenomic, Santa Clara, CA). The dHPLCMelt program was used
to predict the optimal melting conditions for PCR fragments, which
were analyzed on a WAVE DNA fragment analyzer at temperatures
recommended by predicted helicity profiles across the DNA fragment.
Variant dHPLC profiles suggestive of sequence heterogeneity were
sequenced. The WAVE was run under partially denaturing conditions
for mutation detection and SNP discovery. Wavemaker 4.0 software
was used to control the rate of flow of buffers and column running. A
volume of between 4 and 8 l of patient and control PCRs were injected
into the column depending on the DNA concentration of the PCR.
DNA Sequencing—GPHN SNPs were detected by radionucleotide
[-33P] cycle sequencing. Sequencing was initiated using a denaturation
stage at 94 °C for 5 min followed by 45 cycles of primer annealing
temperatures at 55 °C for 30 s, primer extension at 72 °C for 1 min, and
denaturation at 94 °C for 30 s. Denatured samples were applied to a 6%
denaturing polyacrylamide gels (Sigma) and resolved at 85 watts for
1–2 h at room temperature. The sequence content of RT-PCR products
and clones were determined by ABI 3100 equipment using BigDYE
chemistry (PerkinElmer Life Sciences). Each amplimer was sequenced
with sense and antisense primers using an ABI PRISMTM BigDye
Terminator cycle sequencing kit and AmpliTaq DNA polymerase
(PerkinElmer Life Sciences).
Population Studies—The population frequency of identified sequence
variations (potentially pathogenic mutations and SNPs) were estab-
lished in a variable number of unrelated controls of Caucasian descent
and derived from blood donor clinics in New Zealand (Table II). In
instances where a restriction site change was predicted by the polymor-
phism, the relevant restriction fragment length polymorphism assay
was designed and resolved by agarose gel electrophoresis or polyacryl-
amide gel electrophoresis. For those SNPs devoid of restriction site
changes, the SNP frequency in the normal population was determined
by comparison of mutation profiles versus normal profiles using muta-
tion screening techniques SSCP, DDF, or dHPLC (see Table II).
RESULTS
GlyR  Subunit YTH Screen—In an attempt to identify fur-
ther GlyR-interacting proteins that may be implicated in hy-
perekplexia, we carried out a YTH screen of an adult human
brain cDNA library, using the GlyR  subunit TM3-TM4 intra-
cellular loop as bait. The cDNA library had an original com-
plexity of 3.5  106 independent cDNA clones, and 8  106
cDNAs were screened. Twelve positive clones were recovered,
which specifically interacted with the GlyR  subunit bait.
These represented eight independent cDNAs encoding variants
of the human homologue of GPHN (Fig. 1). No other interacting
proteins were found. Some of our gephyrin cDNAs (e.g. Geph1)
were full-length, which allowed us to predict the entire coding
sequence of the human gephyrin polypeptide. Structurally, the
N- and C-terminal domains of gephyrin show high similarity to
E. coli proteins (MogA and MoeA), a Drosophila protein (CIN-
NAMON), and an Arabidopsis thaliana protein (CNX1), all of
which are involved in the synthesis of a molybdenum-contain-
ing co-factor essential for molybdoenzyme activity. Analysis of
the phylogenetic conservation within the human GPHN open
reading frame reveals a 94% homology to rodent gphn sequence
and a 91% homology to chicken sequence, assuming the exclu-
sion of all alternatively transcribed exons. In comparison with
rodents, this is translated into a 99.7% amino acid conservation
(Fig. 2) within the constitutional 736-amino acid reading
frame. Degeneracy is observed at two sites, I240L and A242R,
amino acid changes that lie immediately 5 adjacent to the C3
linker insertion site (30). The amino acid conservation between
chicken and human GPHN is reduced to 98.7%, with all but one
of the nine degenerate changes occurring at the MoeA domain,
and a reversal of the rodent I240L and A242R changes is
observed (Fig. 2).
Interestingly, several of the GlyR -interacting GPHN clones
(Geph5–8) were missing all of the N-terminal MogA homology
domain (amino acids 16–169) as well as most of the “linker”
segment of gephyrin (amino acids 170–322; Fig. 1). This sug-
gests that an intact C-terminal MoeA domain is required for
FIG. 1. Gephyrin clones captured by yeast two-hybrid screen.
Shown is a schematic diagram displaying the domain structure of the
human gephyrin P1 isoform (GephP1) indicating the positions of the
MogA and MoeA homology domains (amino acids 16–169 and 323–736)
and the intervening “linker” segment (amino acids 170–322). Below this
are the structures of the human gephyrin cDNAs isolated in our GlyR
 subunit YTH screen (Geph1–Geph8). Note that some cDNAs con-
tained either C3 (Geph2) or single (Geph3) or multiple (Geph1) C4
cassettes. In addition, all cDNAs encode an intact MoeA homology
domain, suggesting that this region is essential for mediating robust
interactions with the GlyR  subunit.
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strong interactions with the GlyR subunit and that the bind-
ing site on gephyrin for GlyRs does not reside in the MogA
homology domain or the linker region.
Transcript Heterogeneity of Human GPHN—Several vari-
ants of gephyrin were found in our GlyR  subunit YTH screen.
That gephyrin exists in multiple isoforms has been established
for some time (25, 28, 33); the most common variants have
insertions in the “linker” region, where exon C3 inserts the
peptide NHPFYTSPAVFMANHGQPIPGLISYSHHATGSA-
DKR between amino acids 243 and 244, and the C4 exon
inserts the sequence ARLPSCSSTYSVSE between amino acids
288 and 289. More recently, Ramming et al. (25) described
seven alternatively expressed murine exons including three
consecutive C4 exons and two further 5 exons designated C6
and C7. In our Y2H screen and in subsequent RT-PCR
experiments (Fig. 3), we have found that human GPHN has at
least four exons within the C4 cassette cluster; C4A,
QIRRPDESKGVASRVGSLK (identical to original C4b casset-
te) (50); C4B, LHRKLEELRDHLEGNVKGYSLRVNVRFHL
(novel exon); C4C, ARLPSCSSTYSVSE (identical to the orig-
inal C4 cassette) (28); and C4D, LHSRLEGLKDELWRSRG-
YDLR (identical to the original C5 cassette) (25). The C4A-C-
4B-C4C-C4D cluster is physically contiguous on human
chromosome 14 BACS and definitively alters the genomic org-
anization of GPHN (see Fig. 4).
The RT-PCR assays for human GPHN were designed to
capture regions of splicing activity implicated from rodent gphn
studies (Table I). Twelve different human RNA preparations
from neurological (n  4), and nonneurological (n  8) tissues
were tested (see Fig. 3A). The presence of rat gphn exons C1
(region 1) or exon C5* described by David-Watine (27) was not
detected in any of our transcripts from human tissues. Exon C2
(region 1) was ubiquitously expressed in all transcripts with no
suggestion of differential splicing. Furthermore, murine gphn
exons C6 and C7 were not detected; nor was the exclusion of
exon 18 in human GPHN transcripts (25, 51). The transcript
pattern surrounding the C3 and C4 cluster revealed a clear
difference between neurological tissues and nonneurological
tissues. A solitary transcript was found in all nonneurological
tissues, which included the C3 exon and excluded all exons
from the C4 cluster (Fig. 3A). In contrast, neurological tissue
generated a ladder effect, indicating the presence a range of
fragments. The fragments were cloned into pGEM-easy vec-
tors, and a total of 547 clones were PCR-screened for size
differences, from which 86 clones were selected and sequenced.
All of the clones sequenced contained perfectly preserved splic-
ing insertion points and followed the linear 5 to 3 order of
exons on the BAC contig. In total, sequencing confirmed the
presence of 11 distinct neurological GPHN isoforms (Fig. 3B).
The majority of neurological isoforms excluded exon C3 and
contained a combination of the C4 exon cluster; however, two
rare clones were detected that demonstrated the co-inclusion of
exon C3 and one of the C4 cluster exons (Fig. 3B). One isoform
corresponded to the nonneurological pattern by exclusively re-
taining the C3 exon, and this presumably reflects the metabolic
transcript of gephyrin required in all tissues including the
human brain.
To validate our capture of all transcript isoform combina-
tions, further RT-PCRs were generated from an upstream in-
variant forward primer and nested reverse primers within each
spliced exon of the C4 cluster (Table I). This approach captured
all previously identified isoforms and did not reveal any addi-
tional isoform combinations. Finally, additional testing of the
remaining GPHN invariant regions (Table I) found no evidence
to suggest any exonic splicing outside the C3 and C4 exon
cluster.
Mutation Analysis and SNP Distribution in GPHN—Three
highly informative mutation detection techniques (SSCP,
dideoxy fingerprinting, and automated dHPLC) were adopted
to detect GPHN mutations and polymorphisms in a cohort of 32
hyperekplexia patients. Several SNPs were detected in the
promoter, intronic, and exonic regions in both patient and
control cohorts (Table II). In addition, a 4-bp deletion was
detected within the GPHN candidate promoter region (del tgga
at position 976 3 972), which was also detected in normal
controls and was not functionally assessed. Significantly, a
heterozygous missense mutation (A28T) was detected in a hy-
perekplexia patient that causes an asparagine to tyrosine
amino acid substitution (N10Y) in exon 1 of the GPHN gene
(Fig. 5A). There were no restriction site changes for GPHN
A28T, so consequently we analyzed 94 controls by DDF and
confirmed the exclusion of patient-specific patterns from the
control group (Fig. 5B). The N10Y substitution is positioned 5
amino acids upstream from a putative myristoylation site,
which is a conserved marker for protein interactions with a
membrane-bound receptor complex or the lipid bilayer of the
plasma membrane. It was proposed that the N10Y mutation
disturbed this interaction, thereby compromising the GPHN
lattice at an anchorage point, leading to a disruption in GlyR
FIG. 2. Phylogenetic alignment of GPHN. Shown is amino acid
alignment of human, rodent, and chicken GPHN, with shaded regions
representing points of divergence from the human sequence. The ar-
rows indicate the insertion points for the C3 and C4 cluster exons
within the linker region of GPHN. The alignment does not include the
C3/C4 cluster exons in the linker region, but there is 100% conservation
with rat C3 and C4 exons, whereas no comparative data are available
for chicken gephyrin. The MogA and MoeA regions are indicated by
underlined segments of the alignment, and the position of a putative
myristoylation site (*) is indicated (26).
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FIG. 3. RT-PCR assays in putative regions of splicing activity in GPHN. A, each of the four assays has primers anchored on invariant
GPHN-P1 sequence (refer to Table I) and is based on prior knowledge of splicing activity (25, 28). Neurological tissues represent the first four samples
in each gel (left to right: adult brain (lane 1); fetal brain (lane 2); spinal cord (lane 3); cerebellum (lane 4)), and samples 5–12 represent RT-PCR-derived
nonneurological tissue (heart (lane 5); kidney (lane 6); pancreas (lane 7); lung (lane 8); liver (lane 9); fetal liver (lane 10); placenta (lane 11); and trachea
(lane 12)), with lane 13 representing a negative control PCR. Fragments were sized by a 1-kb ladder (Invitrogen). Only the C3 and C4 assays indicated
the presence of transcript heterogeneity. B, size-ordered GPHN-pGEM clones derived from a C3/C4 cluster combination assay and digested with
insert-releasing EcoRI restriction enzyme and resolved on a 10% polyacrylamide gel. In total, 11 neuronal GPHN isoforms were discovered, and each
isoform corresponded to the expected sizes from the possible exonic combinations within the PCR assay. Each of the spliced exons are represented with
distinct patterns, and amino acid translations are provided. Exons in the C4 cluster have been assigned a new nomenclature, and a conversion key
relating to the old nomenclature is provided. Clone 4 was the sole transcript observed in nonneurological tissues (n  8).
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clustering and reduced attenuation of the startle response.
Functional Analysis of GPHN N10Y—To assess whether the
mutation N10Y could affect interactions between GPHN with
the GlyRs or with the GDP/GTP exchange factor collybistin, we
carried out functional expression experiments in transfected
human embryonic kidney cells (HEK293). We used expression
constructs encoding (i) the GlyR  subunit intracellular loop
tagged at the C terminus with red fluorescent protein (DSRed-
GlyR ), (ii) collybistin II (CB2SH3-) tagged at the N terminus
with the 9E10 (Myc) epitope, and (iii) gephyrin P1 wild-type
and N10Y mutants tagged at the N terminus with EGFP. As
expected, DSRed-GlyR  and Myc-CB2SH3 fusion proteins
showed cytoplasmic expression (Fig. 6). In contrast, EGFP-
gephyrin (not shown) and EGFP-gephyrinN10Y formed small
cytoplasmic aggregates that readily trap DSRed-GlyR  (Fig.
6). Since EGFP-gephyrinN10Y is also translocated to the cell
surface by collybistin II, it is unlikely that the N10Y mutation
affects the structural lattice formed by gephyrin or interrupts
gephyrin-GlyR  or gephyrin-collybistin interactions. These
findings are reinforced by our yeast two-hybrid data, which
strongly suggest that the GlyR  binding site on gephyrin is
located within the C-terminal MoeA homology domain.
DISCUSSION
The pleiotropic nature of GPHN demands a molecular expla-
nation, not only to account for the functional differences be-
tween neurological and nonneurological tissues but also to
understand the basis for preferential recruitment and target-
ing of neurotransmitter receptors to the postsynaptic mem-
brane. Derived from an extensive RT-PCR screen of the GPHN
FIG. 4. A revised genomic organization of human GPHN. The previous version of the human GPHN gene described the existence of 27 exons
distributed over 760 kb of genomic DNA on chromosome 14q32 (Fig. 2A). This remains true as a summary; however, our transcript data have led
to a change in the order of exons, the exclusion of human exon C5*, and exclusion of rat C1, C6, and C7 from human GPHN transcripts. Based on
these data, we suggest a new genomic representation of GPHN and a numbering system for all constitutional and spliced exons (Fig. 3B). We
further recommend co-retaining the “C” nomenclatures for the C3 region and the (C4b-C4new-C4-C5) cluster, with revision of the latter to the more
logical labeling of C4A-C4B-C4C-C4D, reflecting the physical genomic organization of these exons within human GPHN.
TABLE I
RT-PCR primers for the spliced regions of GPHN
These primers were used in the generation and capture of human GPHN transcript isoforms. A GPHN-specific primer located at the 3-end of
the gene was used to generate cDNA fragments from mRNA templates derived from neurological (n  4) and nonneurological (n  8) tissues
(Clontech). Primer sets for each candidate region of alternative splicing were designed in regions of the gene that were invariant from tissue to
tissue. In addition, primer sets were designed to analyze the complete reading frame in order to exclude any further regions of exon splicing
(Invariant 1 and 2). The exonic origin of each primer is shown in superscripts. Four nested primers located within each spliced exon were used in
validation experiments to ensure capture of all GPHN transcript isoforms. UTR, untranslated region.
Assay Forward primer 5 3 3 Reverse primer 5 3 3
Exonic 1st Strand
Synthesis Primer ex26GTTCTTGGTGATGCCAAGTTAGTAT
Region C1/2 5-UTRCTTCTCTGGCTCCCTAGCTGT CCTGGCAGGTTAATTATGAGCex6
Region C3 ex7CAGTGGTGTTGCTTCAACAGA GCGATTCTGAAGGAGTAGTGCex9
Region C4/5 ex9ACTCCATCATTTCTCGTGGTG TCAGAGGAAAAGGAGACATGCex14
Region 6/7 ex17ATCGTTTCATCATTGGGGAAT ATTCCCTGTTGACATGACTGCex20
Combinatory C3-C4 ex7CAGTGGTGTTGCTTCAACAGA TCAGAGGAAAAGGAGACATGCex14
Invariant 1 ex14AACATTCTCAGAGCCATCACA CGGACAGCATAGCCATCTTTTex18
Invariant 2 ex20ATCGCCATGACATTAAAAGAG TGATCCTCGTCCAGAATACCAex26
Nested C3-C4A ex7CAGTGGTGTTGCTTCAACAGA TTTGAGGGATCCAACC4A
Nested C3-C4B ex7CAGTGGTGTTGCTTCAACAGA ATTTACTCTGAGAGAC4B
Nested C3-C4C ex7CAGTGGTGTTGCTTCAACAGA CTCAGATACACTATAC4C
Nested C3-C4D ex7CAGTGGTGTTGCTTCAACAGA TCTTAAGTCGTAGCCC4D
TABLE II
Polymorphisms within GPHN
Sequence variations were initially discovered in the cohort of hyperekplexia patients. The approximate population frequency of each GPHN
genotype was assessed in a variable number of unrelated Caucasian control samples using a variety of screening techniques as indicated by RFLP,
DDF, or SSCP. UTR, untranslated region.







972 del (tgga) 5-UTR deletion Unknown 1 from 31 (0.04) 1 from 58 (0.02) SSCP
C-772T SNP Unknown 6 from 31 (0.20) 7 from 38 (0.18) SSCP
A28T (ex 1) Missense mutation N10Y 1 from 31 0 from 94 DDF
IVS1 9(T 3 C) SNP No effect 6 from 31 (0.20) 7 from 32 (0.22) SSCP
IVS3 38(G 3 A) SNP No effect 5 from 31 (0.16) 7 from 32 (0.22) ApoI RFLP
IVS3 6(T 3 C) SNP No effect 3 from 31 (0.10) 2 from 32 (0.07) DDF
T1851C (ex 22) SNP No effect 1 from 31 (0.04) 1 from 48 (0.02) AatII RFLP
IVS24 38(G 3 T) SNP No effect 1 from 31 (0.04) 2 from 32 (0.07) HincII RFLP
IVS24 14(A 3 T) SNP No effect 2 from 31 (0.07) 5 from 48 (0.10) MboII RFLP
IVS25 59(C 3 T) SNP No effect 3 from 31 (0.10) 5 from 48 (0.10) SSCP
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gene and YTH clone capture, we provide evidence for extensive
alternative intense splicing activity in neuronal tissue, which
was in contrast to the single transcript observed in all eight
nonneuronal tissues. The single nonneurological transcript in-
cludes exon C3, an exon that is absent from the majority of
neuronal-specific transcripts, although human brain contains a
mosaic expression of metabolic nonneuronal and heterogene-
ous neuron-specific isoforms. We suggest that the nonneuronal
gephyrin transcript is ubiquitous in human tissues and serves
a metabolic housekeeping purpose as a cofactor in molybdenum
enzyme synthesis.
The substantial combinatory nature of the C4 exon cluster is
created from four alternatively spliced exons, which generate
10 neuronal specific isoforms. The majority of these transcripts
do not retain exon C3; however, two rarely detected isoforms
have retained exon C3 and one of the C4 cluster exons. Three of
the four exons observed in the C4 region have been reported in
rodent tissues (25, 28). One novel exon was detected in human
transcripts and is physically located, in the correct linear order,
within the chromosome 14 BAC contig. Collectively, with the
specific exon to exon construction pattern within all sequenced
isoforms and the BAC contig validation, we are confident that
the 5 3 3 order of the C3 and C4 spliced exons is correct.
There remains a possibility that not all GPHN isoforms have
been captured because of the sheer number of combinatory
possibilities; however, any additional isoforms may be ex-
tremely rare and transcribed in specific areas of the human
brain. In phylogenetic terms, our lack of detection for rodent
exons C1, C6, and C7 in human tissue is also noted by David-
Watine (27). It remains to be seen whether these exons exist,
whether they are so weakly and specifically expressed that we
did not detect them or whether they are an experimental arti-
fact. For a gene that is so highly conserved, it is surprising that
entire exons have been disregarded during recent evolution,
but further work in rodents and human brain sections may be
required to resolve this issue. It is significant, however, that
rodent exons C6 and C7 are not detected, in a conserved or
degenerate manner, within a small region of the chromosome
14 BAC contig containing the expected insertion points be-
tween exons 15 and 19 of GPHN. All remaining 27 human
GPHN exons (including C3 and C4 cluster) are easily detecta-
ble on the BAC contig by BLAST comparison with homologous
rodent exons. In summary, the YTH and PCR results demon-
strate that (i) the complexity of alternative splicing of gephyrin
has been greatly underestimated; (ii) a revised genomic struc-
ture for human GPHN and a simplified nomenclature for the
exons within the C4 cluster is required; (iii) the GlyR  subunit
is capable of interacting with multiple gephyrin isoforms; and
(iv) molecular mechanisms exist whereby gephyrin could reg-
ulate complex associations with different cytoskeletal or cyto-
plasmic proteins at glycinergic versus GABAergic synapses.
The speculative functional consequence of the heterogeneous
GPHN isoforms is attributed to interactions with a complex
repertoire of protein interactions. The present list includes
FIG. 5. Mutation analysis of GPHN in hyperekplexia. A, se-
quence analysis of GPHN exon 1 in a hyperekplexia patient using -33P
cycle sequencing. A synonymous heterozygous change (A28T) was ob-
served in exon 1 of GPHN, resulting in an N10Y amino acid substitu-
tion, positioned 6 residues upstream of a putative myristoylation site
(28). B, a nondenaturing, 10% MDE gel illustrating a population study
to compare patient GPHN A28T and population control DDF patterns.
A patient-specific pattern (indicated by arrows in columns labeled P)
was not detected in unrelated Caucasian control samples (n  94;
samples 1–28 illustrated).
FIG. 6. Functional assessment of GPHN-N10Y. The expression
assays demonstrate that the GPHNN10Y mutation is unlikely to inter-
fere with gephyrin-GlyR  subunit or gephyrin-collybistin interactions.
When expressed alone in HEK293 cells, the GlyR  subunit intracellu-
lar loop tagged with red fluorescent protein (A; DSRed-GlyR ) and
Myc-tagged collybistin II (C; Myc-CB2SH3-) are found throughout the
cell. In contrast, note that EGFP-gephyrinN10Y forms cytoplasmic ag-
gregates (B), which are identical to those formed by EGFP-gephyrin.
EGFP-gephyrinN10Y readily traps DSRed-GlyR  in these cytoplasmic
aggregates (D–F) and is translocated to the cell surface upon co-expres-
sion with collybistin II (G–I). The results reveal no significant differ-
ences compared with control experiments performed using nonmutated
gephyrin (i.e. EGFP-gephyrin; data not shown).
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evidence for protein interactions with the  subunit of the
glycine receptor, tubulin, GABARAP, profilin, collybistin, and
the dynein light chains. Considering that this is probably not
the complete cast of interacting proteins, it becomes apparent
that the splicing activity of C3 and C4 regions of the GPHN
gene may form the basis for differential properties of GPHN
isoforms. The “linker” segment also contains several potential
protein-protein interaction domains including proline-rich and
acidic segments as well as a short motif (amino acids 289–299)
that has strong similarity to the tubulin-binding domain sig-
nature of tau and MAP2/MAP4 proteins (25). This may be of
significance, since the tubulin-binding properties of gephyrin
closely resemble those of mitogen-activated proteins (52).
Given the proximity of the site of insertion for the C4 cassette
to the putative tubulin-binding domain, it is possible that C4
inserts might influence interactions with cytoskeletal proteins.
Interestingly, cassettes C4B and C4D are homologous to
each other and to the -helical region 1B of human keratin 8
(53). This motif is known to mediate keratin dimerization by
the formation of coiled-coil structures. It is possible that inclu-
sion of cassettes C4B and or C4D creates a binding site for a
new gephyrin interactor. Ramming et al. (25) concluded that
gephyrin transcripts containing the C3 and C4 exons were of
low abundance but highly expressed in some subpopulations of
neurons in the adult mouse brain. For example, cassette C4D
was found in the granular cell layer of the cerebellum and
olfactory bulb. However, this study did not take other develop-
mental stages into account (e.g. cassette C3 is highly expressed
throughout the central nervous system early in development)
and did not focus on spinal cord or brainstem. Generating
spliced exon-specific antibodies and immunohistochemical
analysis in rodent and human brain will greatly enhance our
understanding of spatial and temporal distribution of gephyrin
transcripts.
Despite the established association of hyperekplexia muta-
tions with subunits from glycinergic ion channels in both hu-
mans and animal models, it is apparent that mutations in
gephyrin are not a major cause of the disorder. Considering the
high degree of phylogenetic conservation and that GPHN is an
essential metabolic agent, it is possible that mutations in many
regions of GPHN are embryonic lethal. Our promoter and exon
by the exon mutation detection approach revealed a novel
mutation causing a N10Y substitution at the extreme N termi-
nus of GPHN. This portion of gephyrin is not part of the MogA
consensus sequence, which begins at amino acid 15, and this
positioning may be the basis of functional tolerance in the
mutation carrier. Recent crystal structure determination of the
GPHN N-terminal domain indicates a trimeric structure that
presumably is the structural conformation required to form a
subsynaptic lattice (54, 55). The N10Y mutation was found in a
young male infant who presented with neonatal hypertonia
and excessive startle response in the first year of life. At 4 years
of age, there has been a transient recovery of the phenotype
with no features of molybdenum metabolism disruption.
GPHNN10Y may have a limited detrimental window during
developmental glycinergic switching from GlyR 2 homopen-
tamers to GlyR 1 heteropentamers. From a glycinergic per-
spective, GPHNN10Y does not disrupt GlyR-gephyrin interac-
tions in human embryonic kidney cells and does not interrupt
collybistin-induced cell surface clustering. Since in vitro clus-
tering is not affected by GPHNN10Y, the functional effect of this
mutation remains elusive, and an alternative mechanism is
responsible for the hyperekplexia phenotype.
The fact remains, however, that 60% of our sporadic hy-
perekplexia cohort is devoid of GLRA1, GLRB, and GPHN
mutations, and this clearly implies further genetic heterogene-
ity. Casting a wider net for the mutation analysis of glycinergic
transporters and GABAergic candidates may yet yield further
genetic heterogeneity in hyperekplexia. Indeed, recent descrip-
tions of GABAA mutations in epilepsy demonstrates the subtle
functional overlap between the two neuroinhibitory systems
with the resulting phenotypes a reflection of the differential
localizations and function of glycinergic and GABAergic recep-
tor subunit expression.
In conclusion, we have demonstrated the existence of a large
number of neuron-specific gephyrin isoforms that may form the
basis for specialized protein interactions. By identifying all
exon constituents of the gene, we were able to exclude the
gephyrin coding sequence as a major determinant for hyperek-
plexia. Nevertheless, a solitary mutation may yet have a func-
tional explanation in a transient form of the disorder despite
the exclusion of our initial functional hypothesis. We describe a
number of synonymous and flanking intronic SNPs of GPHN
that may be informative for mapping purposes and other dis-
orders linked to chromosome 14q24. Finally, as a consequence
of a YTH search for glycinergic interacting proteins, we can
confirm that the physical location of the GPHN-GlyR  inter-
acting domain in the GPHN molecule does not lie in the MogA
region, linker segment, or C3 and C4 splicing cluster. This
domain lies within the C-terminal portion of the conserved
MoeA region, and the definitive identification of an interacting
GPHN motif represents the next challenge toward character-
izing the physical nature of GPHN-GlyR coupling.
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